Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25028414,absolute bioavailability,Mean absolute bioavailability of oral baclofen was 74%.,A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25028414/),%,74,8773,DB00181,Baclofen
,2023878,blood-brain barrier clearance,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),[μl] / [min],4.7,11661,DB00181,Baclofen
,2023878,blood-brain barrier clearance,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),[μl] / [min],1.1,11662,DB00181,Baclofen
,2023878,blood-brain barrier clearance,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),%,0.031,11663,DB00181,Baclofen
,2023878,blood-brain barrier clearance,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),[μl] / [min],1.0,11664,DB00181,Baclofen
,2023878,blood-brain barrier clearance,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),%,0.036,11665,DB00181,Baclofen
,2023878,cumulative transported amount,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),%,0.085,11666,DB00181,Baclofen
,2023878,cumulative transported amount,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),[μl] / [min],1.1,11667,DB00181,Baclofen
,2023878,cumulative transported amount,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),%,0.031,11668,DB00181,Baclofen
,2023878,cumulative transported amount,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),[μl] / [min],1.0,11669,DB00181,Baclofen
,2023878,cumulative transported amount,"However, for R-baclofen the blood-brain barrier clearance (4.7 +/- 1.0 microliters/min, mean +/- SE; n = 6) and cumulative transported amount (0.085 +/- 0.007%; n = 6) were significantly higher than these values for the S-enantiomer (1.1 +/- 0.3 microliters/min, 0.031 +/- 0.005%; n = 6) and racemic baclofen (1.0 +/- 0.1 microliters/min, 0.036 +/- 0.003%; n = 6).",Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023878/),%,0.036,11670,DB00181,Baclofen
,8971830,Lumbar CSF levels,Lumbar CSF levels were in the range of 44 to 1230 ng/ml.,Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971830/),[ng] / [ml],44 to 1230,37003,DB00181,Baclofen
,25530781,elimination half-life,"Baclofen was rapidly absorbed, showed biexponential decline with elimination half-life of 3.42-4.10 hr, and mostly excreted into urine.",Pharmacokinetic alteration of baclofen by multiple oral administration of herbal medicines in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25530781/),h,3.42-4.10,37190,DB00181,Baclofen
,27867020,Cmax,"After the 20 mg PO and 15 mg IV doses, mean Cmax levels were 255 and 722 ng/mL and half-lives were 5.24 and 5.79 hours for PO and IV baclofen, respectively.",A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27867020/),[ng] / [ml],255,51818,DB00181,Baclofen
,27867020,Cmax,"After the 20 mg PO and 15 mg IV doses, mean Cmax levels were 255 and 722 ng/mL and half-lives were 5.24 and 5.79 hours for PO and IV baclofen, respectively.",A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27867020/),[ng] / [ml],722,51819,DB00181,Baclofen
,27867020,half-lives,"After the 20 mg PO and 15 mg IV doses, mean Cmax levels were 255 and 722 ng/mL and half-lives were 5.24 and 5.79 hours for PO and IV baclofen, respectively.",A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27867020/),h,5.24,51820,DB00181,Baclofen
,27867020,half-lives,"After the 20 mg PO and 15 mg IV doses, mean Cmax levels were 255 and 722 ng/mL and half-lives were 5.24 and 5.79 hours for PO and IV baclofen, respectively.",A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27867020/),h,5.79,51821,DB00181,Baclofen
,27867020,oral bioavailability,The mean oral bioavailability for the 20-mg PO dose was approximately 80%.,A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27867020/),%,80,51822,DB00181,Baclofen
,27867020,bioavailability,The 80% bioavailability suggests that a 20% reduction in IV dose will produce comparable total drug exposures to that of the PO dose.,A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27867020/),%,80,51823,DB00181,Baclofen
,33068797,elimination half-life,"Estimated elimination half-life in the 'RRT' group and the 'no RRT' group were respectively 3.1 [2.2-4.8] h (n = 6 patients) and 3.4 [1.4-5.5] h (n = 19 patients, p = 0.53).",Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33068797/),h,3.1,62653,DB00181,Baclofen
,33068797,elimination half-life,"Estimated elimination half-life in the 'RRT' group and the 'no RRT' group were respectively 3.1 [2.2-4.8] h (n = 6 patients) and 3.4 [1.4-5.5] h (n = 19 patients, p = 0.53).",Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33068797/),h,3.4,62654,DB00181,Baclofen
,33068797,duration,"The median duration of intubation was not significantly different between groups (72 [48-72] h and 72 [24-96] h, respectively; p = 0.38).",Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33068797/),h,72,62655,DB00181,Baclofen
,33068797,duration,"The median duration of intubation was not significantly different between groups (72 [48-72] h and 72 [24-96] h, respectively; p = 0.38).",Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33068797/),h,72,62656,DB00181,Baclofen
,2720132,Vm,"A computer method based on the integrated form of Michaelis-Menten equation which reproduces the entire time course of drug absorption from the data found in three intestinal perfusion series at different initial concentrations, yielded Vm and Km values of 12.0 mg h-1 and 8.0 mg, respectively, in the mean segment of the small intestine, a rather selective absorption site for baclofen.",Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720132/),[mg] / [h],12.0,65911,DB00181,Baclofen
,2720132,Km,"A computer method based on the integrated form of Michaelis-Menten equation which reproduces the entire time course of drug absorption from the data found in three intestinal perfusion series at different initial concentrations, yielded Vm and Km values of 12.0 mg h-1 and 8.0 mg, respectively, in the mean segment of the small intestine, a rather selective absorption site for baclofen.",Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720132/),mg,8.0,65912,DB00181,Baclofen
,9258974,half-life,"After oral administration, the baclofen half-life was 2.3 to 3.4 hours and peak serum concentrations were achieved from 1 to 2.1 hours after administration.",Failure of absorption of baclofen after rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9258974/),h,2.3 to 3.4,69436,DB00181,Baclofen
,32315750,lag times,The prepared beads showed floating properties up to 12 h with different lag times ranging from 45.67 to 72.33 sec.,"Design, characterization and in vivo evaluation of modified release baclofen floating coated beads. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315750/),s,45.67 to 72.33,78878,DB00181,Baclofen
,30190685,absorption constant (Ka),"The pharmacokinetic parameters of baclofen were (bootstrap 95% confidence intervals): absorption constant (Ka) 1.64 1/h (1.34-2), clearance (Cl/F) 11.6 L/h (10.8-12.3) and volume of distribution (Vd/F) 72.8 L (66.5-80.4) leading to a half-life of 4.4 h.",Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30190685/),[1] / [h],1.64,81789,DB00181,Baclofen
,30190685,clearance (Cl/F),"The pharmacokinetic parameters of baclofen were (bootstrap 95% confidence intervals): absorption constant (Ka) 1.64 1/h (1.34-2), clearance (Cl/F) 11.6 L/h (10.8-12.3) and volume of distribution (Vd/F) 72.8 L (66.5-80.4) leading to a half-life of 4.4 h.",Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30190685/),[l] / [h],11.6,81790,DB00181,Baclofen
,30190685,volume of distribution (Vd/F),"The pharmacokinetic parameters of baclofen were (bootstrap 95% confidence intervals): absorption constant (Ka) 1.64 1/h (1.34-2), clearance (Cl/F) 11.6 L/h (10.8-12.3) and volume of distribution (Vd/F) 72.8 L (66.5-80.4) leading to a half-life of 4.4 h.",Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30190685/),l,72.8,81791,DB00181,Baclofen
,30190685,half-life,"The pharmacokinetic parameters of baclofen were (bootstrap 95% confidence intervals): absorption constant (Ka) 1.64 1/h (1.34-2), clearance (Cl/F) 11.6 L/h (10.8-12.3) and volume of distribution (Vd/F) 72.8 L (66.5-80.4) leading to a half-life of 4.4 h.",Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30190685/),h,4.4,81792,DB00181,Baclofen
,22457313,k(CSF),"The mean estimates of the parameters were k(CSF)= 0.105 h(-1) and PC= 0.053, corresponding to mean steady-state doripenem CSF concentrations of 0.20 mg/L and 0.40 mg/L for regimens of 3 × 500 mg daily and 3 × 1000 mg daily, respectively, and a mean equilibrium half-life of 6.6 h.",Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22457313/),1/[h],0.105,87792,DB00181,Baclofen
,22457313,PC,"The mean estimates of the parameters were k(CSF)= 0.105 h(-1) and PC= 0.053, corresponding to mean steady-state doripenem CSF concentrations of 0.20 mg/L and 0.40 mg/L for regimens of 3 × 500 mg daily and 3 × 1000 mg daily, respectively, and a mean equilibrium half-life of 6.6 h.",Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22457313/),,0.05,87793,DB00181,Baclofen
,22457313,steady-state doripenem CSF concentrations,"The mean estimates of the parameters were k(CSF)= 0.105 h(-1) and PC= 0.053, corresponding to mean steady-state doripenem CSF concentrations of 0.20 mg/L and 0.40 mg/L for regimens of 3 × 500 mg daily and 3 × 1000 mg daily, respectively, and a mean equilibrium half-life of 6.6 h.",Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22457313/),[mg] / [l],0.20,87794,DB00181,Baclofen
,22457313,steady-state doripenem CSF concentrations,"The mean estimates of the parameters were k(CSF)= 0.105 h(-1) and PC= 0.053, corresponding to mean steady-state doripenem CSF concentrations of 0.20 mg/L and 0.40 mg/L for regimens of 3 × 500 mg daily and 3 × 1000 mg daily, respectively, and a mean equilibrium half-life of 6.6 h.",Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22457313/),[mg] / [l],0.40,87795,DB00181,Baclofen
,22457313,equilibrium half-life,"The mean estimates of the parameters were k(CSF)= 0.105 h(-1) and PC= 0.053, corresponding to mean steady-state doripenem CSF concentrations of 0.20 mg/L and 0.40 mg/L for regimens of 3 × 500 mg daily and 3 × 1000 mg daily, respectively, and a mean equilibrium half-life of 6.6 h.",Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22457313/),h,6.6,87796,DB00181,Baclofen
,33069710,Partition coefficient,Partition coefficient was found to be 1.27 at pH 7.4.,Preformulation-Assisted Design and Characterization of Modified Release Gastroretentive Floating Extrudates Towards Improved Bioavailability and Minimized Side Effects of Baclofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33069710/),,1.27,91130,DB00181,Baclofen
,33069710,lag time,The prepared extrudates recorded buoyance characteristics for 24 h with a floating lag time varying from 0 to 73.34 s.,Preformulation-Assisted Design and Characterization of Modified Release Gastroretentive Floating Extrudates Towards Improved Bioavailability and Minimized Side Effects of Baclofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33069710/),s,0 to 73.34,91131,DB00181,Baclofen
,28867665,oral,"After univariate analysis of the data, the SNP of ABCC9 (rs11046232, heterozygous AT versus the reference TT genotype) was associated with a 2-fold increase in oral baclofen clearance (mean 0.51 ± standard deviation 0.05 L/h/kg for the AT genotype versus 0.25 ± 0.07 L/h/kg for the TT genotype, adjusted P < .001).",Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28867665/),[l] / [h·kg],0.51,98237,DB00181,Baclofen
,28867665,oral,"After univariate analysis of the data, the SNP of ABCC9 (rs11046232, heterozygous AT versus the reference TT genotype) was associated with a 2-fold increase in oral baclofen clearance (mean 0.51 ± standard deviation 0.05 L/h/kg for the AT genotype versus 0.25 ± 0.07 L/h/kg for the TT genotype, adjusted P < .001).",Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28867665/),[l] / [h·kg],0.25,98238,DB00181,Baclofen
,28867665,clearance,"After univariate analysis of the data, the SNP of ABCC9 (rs11046232, heterozygous AT versus the reference TT genotype) was associated with a 2-fold increase in oral baclofen clearance (mean 0.51 ± standard deviation 0.05 L/h/kg for the AT genotype versus 0.25 ± 0.07 L/h/kg for the TT genotype, adjusted P < .001).",Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28867665/),[l] / [h·kg],0.51,98239,DB00181,Baclofen
,28867665,clearance,"After univariate analysis of the data, the SNP of ABCC9 (rs11046232, heterozygous AT versus the reference TT genotype) was associated with a 2-fold increase in oral baclofen clearance (mean 0.51 ± standard deviation 0.05 L/h/kg for the AT genotype versus 0.25 ± 0.07 L/h/kg for the TT genotype, adjusted P < .001).",Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28867665/),[l] / [h·kg],0.25,98240,DB00181,Baclofen
,22901056,lag time,"Optimized formulation showed floating lag time of 4-5 s, floated for more than 12 h and released the drug in sustained manner.","Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901056/),s,4-5,118588,DB00181,Baclofen
,22901056,Cmax,In vivo pharmacokinetic studies in rabbits showed Cmax of 189.96 ± 13.04 ng/mL and Tmax of 4 ± 0.35 h for GFDDS.,"Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901056/),[ng] / [ml],189.96,118589,DB00181,Baclofen
,22901056,Tmax,In vivo pharmacokinetic studies in rabbits showed Cmax of 189.96 ± 13.04 ng/mL and Tmax of 4 ± 0.35 h for GFDDS.,"Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901056/),h,4,118590,DB00181,Baclofen
greater,1871049,half-life,"Products chosen fulfilled one of the following three criteria: (1) a high ""apparent intrasubject variability"" and a half-life greater than 8 hr (danazol); (2) a low apparent intrasubject variability and a half-life less than 4 hr (baclofen); and (3) products exhibiting a low apparent intrasubject variability and a half-life greater than 8 hr (oxazepam).",Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871049/),h,8,123998,DB00181,Baclofen
less,1871049,half-life,"Products chosen fulfilled one of the following three criteria: (1) a high ""apparent intrasubject variability"" and a half-life greater than 8 hr (danazol); (2) a low apparent intrasubject variability and a half-life less than 4 hr (baclofen); and (3) products exhibiting a low apparent intrasubject variability and a half-life greater than 8 hr (oxazepam).",Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871049/),h,4,123999,DB00181,Baclofen
less,1871049,elimination half-life,"On the other hand, AUCO-LAST worked best with a high fractional standard deviation (fsd) and a short elimination half-life (i.e., less than 4 hr).",Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871049/),h,4,124000,DB00181,Baclofen
up to,19502531,bioavailability,Sustained release formulations of arbaclofen placarbil demonstrated sustained R-baclofen exposure in dogs with bioavailability up to 68%.,"Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19502531/),%,68,124978,DB00181,Baclofen
,26207768,BE50,"The proportion of patients being classified as responders was 38% (95% confidence interval [CI] 7 to 76), the maximal decrease in OCDS (Emax ) was 72% (95% CI 25 to 85), and the BE50 was 12.6 (95% CI 0.02 to 74.3) or 4,390 (95% CI 20.4 to 31,800) h mg/l for responders and nonresponders, respectively.",Anticraving Effect of Baclofen in Alcohol-Dependent Patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207768/),[h·mg] / [l],12.6,130125,DB00181,Baclofen
,26207768,BE50,"The proportion of patients being classified as responders was 38% (95% confidence interval [CI] 7 to 76), the maximal decrease in OCDS (Emax ) was 72% (95% CI 25 to 85), and the BE50 was 12.6 (95% CI 0.02 to 74.3) or 4,390 (95% CI 20.4 to 31,800) h mg/l for responders and nonresponders, respectively.",Anticraving Effect of Baclofen in Alcohol-Dependent Patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207768/),[h·mg] / [l],"4,390",130126,DB00181,Baclofen
,20006596,K(i),SCH 486757 selectively binds human NOP receptor (K(i)=4.6+/-0.61nM) over classical opioid receptors.,Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006596/),nM,4.6,132212,DB00181,Baclofen
,2050171,elimination half-life,The elimination half-life ranged from 0.9 to 5 h and the clearance from 0.013 to 0.08 l.h-1.,CSF baclofen levels after intrathecal administration in severe spasticity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050171/),h,0.9 to 5,141396,DB00181,Baclofen
,2050171,clearance,The elimination half-life ranged from 0.9 to 5 h and the clearance from 0.013 to 0.08 l.h-1.,CSF baclofen levels after intrathecal administration in severe spasticity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050171/),[l] / [h],0.013 to 0.08,141397,DB00181,Baclofen
,12554140,extraction recovery,"The average extraction recovery was 81.6% for R-(-)-baclofen, 83.0% for S-(+)-baclofen and 94.0% for the internal standard (p-aminobenzoic acid).",Chiral separation and determination of R-(-)- and S-(+)-baclofen in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12554140/),%,81.6,142763,DB00181,Baclofen
,12554140,extraction recovery,"The average extraction recovery was 81.6% for R-(-)-baclofen, 83.0% for S-(+)-baclofen and 94.0% for the internal standard (p-aminobenzoic acid).",Chiral separation and determination of R-(-)- and S-(+)-baclofen in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12554140/),%,83.0,142764,DB00181,Baclofen
,12554140,extraction recovery,"The average extraction recovery was 81.6% for R-(-)-baclofen, 83.0% for S-(+)-baclofen and 94.0% for the internal standard (p-aminobenzoic acid).",Chiral separation and determination of R-(-)- and S-(+)-baclofen in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12554140/),%,94.0,142765,DB00181,Baclofen
,17764008,removal rate constant,The pharmacokinetics calculations revealed a baclofen haemodialysis removal rate constant of 0.152 h(-1) and a haemodialysis clearance of 2.14 mL/s.,Haemodialysis clearance of baclofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17764008/),1/[h],0.152,147570,DB00181,Baclofen
,17764008,clearance,The pharmacokinetics calculations revealed a baclofen haemodialysis removal rate constant of 0.152 h(-1) and a haemodialysis clearance of 2.14 mL/s.,Haemodialysis clearance of baclofen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17764008/),[ml] / [s],2.14,147571,DB00181,Baclofen
,12548151,plasma clearance (Cl),Mean plasma clearance (Cl) was 315.9 mL/h/kg; volume of distribution (Vd) was 2.58 L/kg; and half-life (T(1/2)beta) was 5.10 hours.,Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548151/),[ml] / [h·kg],315.9,149012,DB00181,Baclofen
,12548151,volume of distribution (Vd),Mean plasma clearance (Cl) was 315.9 mL/h/kg; volume of distribution (Vd) was 2.58 L/kg; and half-life (T(1/2)beta) was 5.10 hours.,Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548151/),[l] / [kg],2.58,149013,DB00181,Baclofen
,12548151,half-life (T(1/2)beta),Mean plasma clearance (Cl) was 315.9 mL/h/kg; volume of distribution (Vd) was 2.58 L/kg; and half-life (T(1/2)beta) was 5.10 hours.,Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548151/),h,5.10,149014,DB00181,Baclofen
,30826461,absorption latency time,"In this population, pharmacokinetic parameters [absorption latency time = 0.37 h, absorption constant rate = 2.2 h-1, apparent volume of distribution = 105 L, apparent clearance (l/h) = 13.5 × (GFR/103)0.839] were characterized by modified absorption and the influence of renal function: renal failure significantly increased baclofen exposure (p = .007) and significantly decreased baclofen clearance (p = .007) compared with patients without renal failure.",Pharmacokinetics and toxicity of high-dose baclofen in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826461/),h,0.37,149082,DB00181,Baclofen
,30826461,absorption constant rate,"In this population, pharmacokinetic parameters [absorption latency time = 0.37 h, absorption constant rate = 2.2 h-1, apparent volume of distribution = 105 L, apparent clearance (l/h) = 13.5 × (GFR/103)0.839] were characterized by modified absorption and the influence of renal function: renal failure significantly increased baclofen exposure (p = .007) and significantly decreased baclofen clearance (p = .007) compared with patients without renal failure.",Pharmacokinetics and toxicity of high-dose baclofen in ICU patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826461/),1/[h],2.2,149083,DB00181,Baclofen
,30826461,apparent volume of distribution,"In this population, pharmacokinetic parameters [absorption latency time = 0.37 h, absorption constant rate = 2.2 h-1, apparent volume of distribution = 105 L, apparent clearance (l/h) = 13.5 × (GFR/103)0.839] were characterized by modified absorption and the influence of renal function: renal failure significantly increased baclofen exposure (p = .007) and significantly decreased baclofen clearance (p = .007) compared with patients without renal failure.",Pharmacokinetics and toxicity of high-dose baclofen in ICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826461/),l,105,149084,DB00181,Baclofen
,2715253,flow-rate,"An isocratic mobile phase containing 0.01 M monobasic potassium phosphate (pH congruent to 3.5)-acetonitrile (80:20, v/v) was delivered at a flow-rate of 1.0 ml/min through the chromatographic system.",Simple and rapid reversed-phase high-performance liquid chromatographic determination of baclofen in human plasma with ultraviolet detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715253/),[ml] / [min],1.0,153169,DB00181,Baclofen
,2715253,limit of detection,The limit of detection for the assay of racemic baclofen was 35 ng/ml.,Simple and rapid reversed-phase high-performance liquid chromatographic determination of baclofen in human plasma with ultraviolet detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715253/),[ng] / [ml],35,153170,DB00181,Baclofen
,29091319,clearance (CL/F),"A one-compartment model with first-order absorption and elimination allowed to determine mean values for clearance (CL/F), volume of distribution (V/F) and absorption rate constant at 8.0 L/h, 44.5 L and 2.23 h-1 , respectively.",Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29091319/),[l] / [h],8.0,165712,DB00181,Baclofen
,29091319,volume of distribution (V/F),"A one-compartment model with first-order absorption and elimination allowed to determine mean values for clearance (CL/F), volume of distribution (V/F) and absorption rate constant at 8.0 L/h, 44.5 L and 2.23 h-1 , respectively.",Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29091319/),l,44.5,165713,DB00181,Baclofen
,29091319,absorption rate constant,"A one-compartment model with first-order absorption and elimination allowed to determine mean values for clearance (CL/F), volume of distribution (V/F) and absorption rate constant at 8.0 L/h, 44.5 L and 2.23 h-1 , respectively.",Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29091319/),1/[h],2.23,165714,DB00181,Baclofen
,15919163,CSF clearance,Baclofen CSF clearance (mean = 8.59+/-2.43 ml/h) and volume of distribution (21.06+/-13.32 ml) were not significantly affected by the increase of the dose (p > 0.05).,Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919163/),[ml] / [h],8.59,173889,DB00181,Baclofen
,15919163,volume of distribution,Baclofen CSF clearance (mean = 8.59+/-2.43 ml/h) and volume of distribution (21.06+/-13.32 ml) were not significantly affected by the increase of the dose (p > 0.05).,Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919163/),ml,21.06,173890,DB00181,Baclofen
,2792173,half-life,"The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data.",Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792173/),h,6.80,175073,DB00181,Baclofen
,2792173,renal excretion rate constant,"The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance.",Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792173/),1/[h],0.35,175074,DB00181,Baclofen
up to,24607242,maximum tolerated dose,Children (2-17 years of age) with CP received a dose of titrated oral baclofen from 2.5 mg 3 times a day to a maximum tolerated dose of up to 20 mg 4 times a day.,Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607242/),mg,20,183303,DB00181,Baclofen
,24607242,terminal half-life,Average baclofen terminal half-life was 4.5 hours.,Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607242/),h,4.5,183304,DB00181,Baclofen
,24607242,apparent clearance/F,"The mean population estimate of apparent clearance/F was 0.273 L/h/kg with 33.4% inter-individual variability (IIV), and the apparent volume of distribution (Vss/F) was 1.16 L/kg with 43.9% IIV.",Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607242/),[l] / [h·kg],0.273,183305,DB00181,Baclofen
,24607242,apparent volume of distribution (Vss/F),"The mean population estimate of apparent clearance/F was 0.273 L/h/kg with 33.4% inter-individual variability (IIV), and the apparent volume of distribution (Vss/F) was 1.16 L/kg with 43.9% IIV.",Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607242/),[l] / [kg],1.16,183306,DB00181,Baclofen
,24607242,mean transit time,Delayed absorption was expressed by a mean transit time of 0.389 hours with 83.7% IIV.,Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607242/),h,0.389,183307,DB00181,Baclofen
,6492227,t1/2,"In contrast to earlier reports, no increase in the plasma half-life of elimination of baclofen could be observed (t1/2 = 4.58 hours).",Pharmacokinetics in baclofen overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492227/),h,4.58,196949,DB00181,Baclofen
,6492227,plasma clearance (Clpl,"On the contrary, we found an increased plasma clearance (Clpl = 0.368 l/kg) in this highly intoxicated patient compared to the kinetics usually found in healthy subjects.",Pharmacokinetics in baclofen overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492227/),[l] / [kg],0.368,196950,DB00181,Baclofen
,3988864,Recoveries,"Recoveries of standards added to plasma and urine were 92% and 93%, respectively.",High-performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivatization with o-phthaldialdehyde. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988864/),%,92,203534,DB00181,Baclofen
,3988864,Recoveries,"Recoveries of standards added to plasma and urine were 92% and 93%, respectively.",High-performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivatization with o-phthaldialdehyde. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988864/),%,93,203535,DB00181,Baclofen
,27879195,t<sub>max</sub>,"The median t<sub>max</sub> of the test and the reference formulation were 1.50 and 1.25 hours, respectively.",Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27879195/),h,1.50,218728,DB00181,Baclofen
,27879195,t<sub>max</sub>,"The median t<sub>max</sub> of the test and the reference formulation were 1.50 and 1.25 hours, respectively.",Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27879195/),h,1.25,218729,DB00181,Baclofen
,27879195,C<sub>max</sub>,"The mean (± SD) C<sub>max</sub> of the test and the reference formulation were 141.401 ± 29.447 ng/mL and 138.837 ± 31.392 ng/mL, respectively.",Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27879195/),[ng] / [ml],141.401,218730,DB00181,Baclofen
,27879195,C<sub>max</sub>,"The mean (± SD) C<sub>max</sub> of the test and the reference formulation were 141.401 ± 29.447 ng/mL and 138.837 ± 31.392 ng/mL, respectively.",Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27879195/),[ng] / [ml],138.837,218731,DB00181,Baclofen
,27879195,AUC<sub>last</sub>,"The mean (± SD) AUC<sub>last</sub> of the two formulations were 702.404 ± 82.149 ng×h/mL and 726.803 ± 90.638 ng×h/mL, respectively.",Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27879195/),[h·ng] / [ml],702.404,218732,DB00181,Baclofen
,27879195,AUC<sub>last</sub>,"The mean (± SD) AUC<sub>last</sub> of the two formulations were 702.404 ± 82.149 ng×h/mL and 726.803 ± 90.638 ng×h/mL, respectively.",Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27879195/),[h·ng] / [ml],726.803,218733,DB00181,Baclofen
,4028618,distribution phase constant (alpha),The average distribution phase constant (alpha) was 1.29 hours-1 and the average elimination phase constant (beta) was 0.191 hours-1.,The pharmacokinetics of baclofen derived from intestinal infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),1/[h],1.29,223607,DB00181,Baclofen
,4028618,elimination phase constant (beta),The average distribution phase constant (alpha) was 1.29 hours-1 and the average elimination phase constant (beta) was 0.191 hours-1.,The pharmacokinetics of baclofen derived from intestinal infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),1/[h],0.191,223608,DB00181,Baclofen
,4028618,volume of the central compartment (Vc/F),"Average volume of the central compartment (Vc/F), volume of the body compartment (Varea/F), systemic clearance (CL/F), and renal clearance were 28.8 L, 59.0 L, 180 ml/min, and 103 ml/min, respectively.",The pharmacokinetics of baclofen derived from intestinal infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),l,28.8,223609,DB00181,Baclofen
,4028618,volume of the body compartment (Varea/F),"Average volume of the central compartment (Vc/F), volume of the body compartment (Varea/F), systemic clearance (CL/F), and renal clearance were 28.8 L, 59.0 L, 180 ml/min, and 103 ml/min, respectively.",The pharmacokinetics of baclofen derived from intestinal infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),l,59.0,223610,DB00181,Baclofen
,4028618,volume of the body compartment (Varea/F),"Average volume of the central compartment (Vc/F), volume of the body compartment (Varea/F), systemic clearance (CL/F), and renal clearance were 28.8 L, 59.0 L, 180 ml/min, and 103 ml/min, respectively.",The pharmacokinetics of baclofen derived from intestinal infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),[ml] / [min],180,223611,DB00181,Baclofen
,4028618,systemic clearance (CL/F),"Average volume of the central compartment (Vc/F), volume of the body compartment (Varea/F), systemic clearance (CL/F), and renal clearance were 28.8 L, 59.0 L, 180 ml/min, and 103 ml/min, respectively.",The pharmacokinetics of baclofen derived from intestinal infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),l,59.0,223612,DB00181,Baclofen
,4028618,systemic clearance (CL/F),"Average volume of the central compartment (Vc/F), volume of the body compartment (Varea/F), systemic clearance (CL/F), and renal clearance were 28.8 L, 59.0 L, 180 ml/min, and 103 ml/min, respectively.",The pharmacokinetics of baclofen derived from intestinal infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),[ml] / [min],180,223613,DB00181,Baclofen
,4028618,renal clearance,"Average volume of the central compartment (Vc/F), volume of the body compartment (Varea/F), systemic clearance (CL/F), and renal clearance were 28.8 L, 59.0 L, 180 ml/min, and 103 ml/min, respectively.",The pharmacokinetics of baclofen derived from intestinal infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028618/),[ml] / [min],103,223614,DB00181,Baclofen
,24033763,clearance (CL),"The population typical mean (95% confidence interval [95% CI]) values for clearance (CL), apparent volume of distribution (V), and rate constant of absorption (Ka) were 9.9 l/h (9.0 to 11.1), 80.7 l (63.6 to 96.9), and 4.6/h (1.5 to 19.9), respectively.",High variability in the exposure of baclofen in alcohol-dependent patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033763/),[l] / [h],9.9,230803,DB00181,Baclofen
,24033763,apparent volume of distribution (V),"The population typical mean (95% confidence interval [95% CI]) values for clearance (CL), apparent volume of distribution (V), and rate constant of absorption (Ka) were 9.9 l/h (9.0 to 11.1), 80.7 l (63.6 to 96.9), and 4.6/h (1.5 to 19.9), respectively.",High variability in the exposure of baclofen in alcohol-dependent patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033763/),l,80.7,230804,DB00181,Baclofen
,24033763,rate constant of absorption (Ka),"The population typical mean (95% confidence interval [95% CI]) values for clearance (CL), apparent volume of distribution (V), and rate constant of absorption (Ka) were 9.9 l/h (9.0 to 11.1), 80.7 l (63.6 to 96.9), and 4.6/h (1.5 to 19.9), respectively.",High variability in the exposure of baclofen in alcohol-dependent patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033763/),1/[h],4.6,230805,DB00181,Baclofen
,21955965,Oral bioavailability,Oral bioavailability was 0.66 and 0.69 in 2 dogs.,Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21955965/),,0.66,230904,DB00181,Baclofen
,21955965,Oral bioavailability,Oral bioavailability was 0.66 and 0.69 in 2 dogs.,Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21955965/),,0.69,230905,DB00181,Baclofen
,21955965,terminal phase half-lives,"Following IV baclofen, terminal phase half-lives were 3.3 and 3.6 hours.",Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21955965/),h,3.3,230906,DB00181,Baclofen
,21955965,terminal phase half-lives,"Following IV baclofen, terminal phase half-lives were 3.3 and 3.6 hours.",Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21955965/),h,3.6,230907,DB00181,Baclofen
,24697865,distribution,"The mean distribution and elimination half-lives were 11 min and 222 min, respectively.",Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697865/),min,11,238242,DB00181,Baclofen
,24697865,elimination half-lives,"The mean distribution and elimination half-lives were 11 min and 222 min, respectively.",Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697865/),min,222,238243,DB00181,Baclofen
,2336342,total body clearance,"The total body clearance averaged 175 ml.min-1 (+/- 44), plasma protein binding 35% (+/- 6).",Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2336342/),[ml] / [min],175,241015,DB00181,Baclofen
,2336342,plasma protein binding,"The total body clearance averaged 175 ml.min-1 (+/- 44), plasma protein binding 35% (+/- 6).",Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2336342/),%,35,241016,DB00181,Baclofen
,31936209,flow rate,"The detection and separation of analytes was achieved on a 48 °C-heated Crownpak CR(+) column (150 mm × 4.0 mm, 5μ) with elution using 0.4% formic acid (FA) in water and 0.4% FA in acetonitrile as the mobile phase running at a flow rate of 1.0 mL/min.",Simultaneous Quantitation of S(+)- and R(-)-Baclofen and Its Metabolite in Human Plasma and Cerebrospinal Fluid using LC-APCI-MS/MS: An Application for Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31936209/),[ml] / [min],1.0,250523,DB00181,Baclofen
up to,25567218,half-lives,"Prolonged half-lives of baclofen, of up to 34 h, have been reported in patients after overdose.",Baclofen overdose treated with continuous venovenous hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567218/),h,34,258009,DB00181,Baclofen
,25567218,elimination half-life,"Concentrations of baclofen in hemofiltrate were within the same range (between 0.74 and 0.05 mg/L), and the elimination half-life during hemofiltration was estimated at 4.8 h.",Baclofen overdose treated with continuous venovenous hemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567218/),h,4.8,258010,DB00181,Baclofen
,25567218,Total clearance,"Total clearance and clearance via hemofiltration were estimated at 6.6 and 2.4 L/h, indicating that clearance could be increased by approximately 57 % by applying hemofiltration.",Baclofen overdose treated with continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567218/),[l] / [h],6.6,258011,DB00181,Baclofen
,25567218,clearance,"Total clearance and clearance via hemofiltration were estimated at 6.6 and 2.4 L/h, indicating that clearance could be increased by approximately 57 % by applying hemofiltration.",Baclofen overdose treated with continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567218/),[l] / [h],2.4,258012,DB00181,Baclofen
,8786954,CLin,"The estimated values of CLin and keff were 0.00157 +/- 0.00076 ml/min/g of brain and 0.0872 +/- 0.0252 min-1, respectively.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g·min],0.00157,262741,DB00181,Baclofen
,8786954,keff,"The estimated values of CLin and keff were 0.00157 +/- 0.00076 ml/min/g of brain and 0.0872 +/- 0.0252 min-1, respectively.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),1/[min],0.0872,262742,DB00181,Baclofen
,8786954,efflux clearance (CLout),"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g],0.816,262743,DB00181,Baclofen
,8786954,efflux clearance (CLout),"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [brain·g·min],0.0712,262744,DB00181,Baclofen
,8786954,keff,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g],0.816,262745,DB00181,Baclofen
,8786954,keff,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [brain·g·min],0.0712,262746,DB00181,Baclofen
,8786954,Vd,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g],0.816,262747,DB00181,Baclofen
,8786954,Vd,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [brain·g·min],0.0712,262748,DB00181,Baclofen
